EBITDA at other companies
Other financials
Where this comes from
Calculated from Protagonist Therapeutics’s reported figures.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's EBITDA?
- Protagonist Therapeutics (PTGX) reported EBITDA of -$3.24M in Q1 2026.
- How has Protagonist Therapeutics's EBITDA changed year-over-year?
- Protagonist Therapeutics's EBITDA increased by 83.0% year-over-year, from -$19.07M to -$3.24M.
- What is the long-term trend for Protagonist Therapeutics's EBITDA?
- Over 3 years (2021 to 2025), Protagonist Therapeutics's EBITDA has grown at a 7.8% compound annual growth rate (CAGR), from -$125.03M to -$156.85M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.